Kentucky Rules Do Not Allow Compounding of Six Peptides Despite HHS Peptide Enforcement Policy

November 20, 2026

businesswoman with arms crossed in an x, signifying "no"

The Kentucky Board of Pharmacy has issued a new compliance alert making clear that the recent federal enforcement discretion policy for six peptide bulk drug substances does not authorize their compounding in Kentucky.

As recently discussed, the U.S. Department of Health and Human Services (HHS) announced an interim policy on October 30, 2026, under which the federal government does not intend to take enforcement action against certain 503A compounders using six peptide bulk drug substances, provided specified conditions are met. The six peptides are BPC-157, TB-500 (thymosin beta-4 fragment), Epitalon, Semax, KPV and MOTS-c.

Importantly, the HHS policy is an exercise of federal enforcement discretion. It does not approve these substances, add them to the FDA’s 503A Bulks List, or override state requirements governing pharmacy compounding.

On November 18, the Kentucky Board of Pharmacy voted to enforce its existing compounding regulation, 201 KAR 2:076, as written and declined to grant waivers that would permit compounding of the six peptides covered by the HHS policy.

Under Kentucky’s rule, a drug compounded for human use must meet one of several requirements. Among other options, it may be compounded from a component of an FDA-approved human drug or from a substance appearing on the FDA’s list of bulk drug substances that may be used in compounding under Section 503A. According to the Board, none of the six peptides covered by HHS’s interim policy currently satisfies Kentucky’s requirements.

As a result, the Board has instructed pharmacies not to compound, dispense or ship preparations containing these substances to patients or practitioners in Kentucky. This restriction also applies to nonresident pharmacies shipping compounded preparations into the state.

Federal enforcement discretion does not necessarily mean that compounding is permitted under state law. For medical spas, prescribers and pharmacies considering whether the HHS policy creates new opportunities to use these peptides, Kentucky provides an early example of why state-specific review remains essential. Before relying on the interim federal policy, providers should confirm that their state pharmacy, medical and other applicable laws permit the contemplated activity.

Kentucky is unlikely to be the last state to address this issue. As regulators evaluate the HHS policy and its interaction with existing state compounding requirements, we are likely to see additional state boards provide guidance or clarification. Practices considering these peptides should therefore continue to monitor developments in their states and review applicable state law before proceeding.

Stay up to date with the latest board comments, bills and policies that impact your practice by becoming a member of the American Med Spa Association. Check for legislative activity in your state >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • CGI Digital Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • Injectable PDGF Enters New Aesthetic Trials for Facial Skin Quality and Infraorbital Hollows
    • Hims & Hers Launches Peptides+ for Men